Bavarian Nordic Announces Interim Results for the First Three Months of 2026

About this update from Bavarian Nordic A/s

COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2026. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “Our Travel Health business continues the strong performance, delivering a 14% growth year-over-year, when adjusting for the discontinued partnerships. This underlines our solid focus on organic growth in existing markets, in particular driven by our rabies vaccine, but also by the continued launch of the chikungunya vaccine across new markets. This year, we have launched our vaccine in the Benelux countries, which will be fully onboarded by mid-2026, where also Switzerland will get access to our vaccine after the recent approval by Swissmedic. We also made important advances in our access strategy for the chikungunya vaccine through strategic partnerships in India and Brazil. In our Public Preparedness business, we keep advancing our mpox/smallpox vaccine program and have recently submitted data to EMA to support extension of the approval for children 2-11 years later this year. With our recent contract award from the U.S. government and a broadened customer base, we are well on track to deliver revenue above the communicated base level of DKK 1.5 to 2 billion from this business, despite no expected material impact from outbreaks.” Highlights from the first quarter Events after the reporting date Conference call and webcast The management of Bavarian Nordic will host an investor/analyst call today at 2 pm CEST (8 am EDT) to present the interim results followed by a Q&A session. A listen-only version of the call and presentation slides can be accessed via https://edge.media-server.com/mmc/p/ghuqepww/ . To join the Q&A session, please register in advance via https://register-conf.media-server.com/register/BIcdc5fa6b4c444d518b6cd3d9cbb5d99b . About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Europe: Disa Tuominen, IR Manager, [email protected] US: Graham Morrell, Gilmartin Group, [email protected] , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Affairs, [email protected] , Tel: +45 53 88 06 03 Company Announcement no. 24 / 2026 Attachments

View stock analysis, news, and events for Bavarian Nordic A/s